First-line treatment of Waldenström's disease with cladribine

  title={First-line treatment of Waldenstr{\"o}m's disease with cladribine},
  author={Michael A Fridrik and Gerald Jaeger and Christian Baldinger and O. v. Krieger and Andreas Chott and Peter Bettelheim},
  journal={Annals of Hematology},
 Purpose: To assess the activity and side effects of cladribine (2-CdA) treatment in patients with advanced Waldenström's disease. Patients and methods: Ten symptomatic patients without prior therapy were included in a prospective multicenter trial. 2-CdA was administered daily at 0.12 mg/kg body weight in a 2-h i.v. infusion over 5 consecutive days; this was repeated every 28 days for four cycles. Patients achieving a remission received interferon alfa-2c (IF) 15 μg s.c. three times a week for… CONTINUE READING


Publications citing this paper.
Showing 1-8 of 8 extracted citations

Neoplastic Diseases of the Blood

Springer International Publishing • 2018
View 10 Excerpts
Highly Influenced

Diagnosis and management of Waldenstrom's macroglobulinemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2005


Publications referenced by this paper.
Showing 1-10 of 15 references

2-Chlorodeoxyadenosine (2CDA) in pretreated low-grade non-Hodgkin’s lymphoma (NHL) patients: lower frequency of infections with maintained high response rate after dose reduction

DC Betticher, T Egger, +4 authors T Cerny
Ann Oncol • 1996
View 2 Excerpts

Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 1994
View 3 Excerpts

Long term results and disease characteristics of patients with Waldenström’s macroglobulinemia treated with the M-2

DC Case, TJ Ervin, MA Boyd
protocol. Blood • 1993
View 1 Excerpt

Similar Papers

Loading similar papers…